Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.

Kamat AM, Lerner SP, O'Donnell M, Georgieva MV, Yang M, Inman BA, Kassouf W, Boorjian SA, Tyson MD, Kulkarni GS, Chang SS, Konety BR, Svatek RS, Balar A, Witjes JA.

Eur Urol Oncol. 2020 Mar 19. pii: S2588-9311(20)30031-6. doi: 10.1016/j.euo.2020.02.006. [Epub ahead of print] Review.

PMID:
32201133
2.

Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A.

J Natl Compr Canc Netw. 2020 Mar;18(3):329-354. doi: 10.6004/jnccn.2020.0011.

PMID:
32135513
3.
4.

Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancer.

Sloan FA, Yashkin AP, Akushevich I, Inman BA.

Urol Oncol. 2020 Feb;38(2):39.e11-39.e19. doi: 10.1016/j.urolonc.2019.10.016. Epub 2019 Nov 21.

PMID:
31761612
5.

Heated Intravesical Chemotherapy: Biology and Clinical Utility.

Tan WP, Longo TA, Inman BA.

Urol Clin North Am. 2020 Feb;47(1):55-72. doi: 10.1016/j.ucl.2019.09.008. Review.

PMID:
31757301
6.

Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer.

Apolo AB, Milowsky MI, Kim L, Inman BA, Kamat AM, Steinberg G, Bagheri M, Krishnasamy VP, Marko J, Dinney CP, Bangs R, Sweis RF, Maher VE, Ibrahim A, Liu K, Werntz R, Cross F, Beaver JA, Singh H, Pazdur R, Blumenthal GM, Lerner SP, Bajorin DF, Rosenberg JE, Agrawal S.

JAMA Oncol. 2019 Oct 31:1-9. doi: 10.1001/jamaoncol.2019.4114. [Epub ahead of print]

PMID:
31670753
7.

Reply by Authors.

Lotan Y, Inman BA, Davis LG, Kassouf W, Messing E, Daneshmand S, Canter D, Marble HT, Joseph AM, Jewell S, Boorjian SA.

J Urol. 2020 Mar;203(3):625-626. doi: 10.1097/JU.0000000000000625. Epub 2019 Oct 25. No abstract available.

PMID:
31651229
8.

Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer.

Grimberg DC, Shah A, Inman BA.

Eur Urol Focus. 2019 Sep 24. pii: S2405-4569(19)30282-2. doi: 10.1016/j.euf.2019.09.006. [Epub ahead of print]

PMID:
31561993
9.

Impact of an enhanced recovery pathway on length of stay and complications in elective radical cystectomy: a before and after cohort study.

Dunkman WJ, Manning MW, Whittle J, Hunting J, Rampersaud EN, Inman BA, Thacker JK, Miller TE.

Perioper Med (Lond). 2019 Aug 22;8:9. doi: 10.1186/s13741-019-0120-4. eCollection 2019.

10.

The Cost to Medicare of Bladder Cancer Care.

Sloan FA, Yashkin AP, Akushevich I, Inman BA.

Eur Urol Oncol. 2019 Feb 8. pii: S2588-9311(19)30016-1. doi: 10.1016/j.euo.2019.01.015. [Epub ahead of print]

PMID:
31412015
11.

Diet and Exercise Are not Associated with Skeletal Muscle Mass and Sarcopenia in Patients with Bladder Cancer.

Wang Y, Chang A, Tan WP, Fantony JJ, Gopalakrishna A, Barton GJ, Wischmeyer PE, Gupta RT, Inman BA.

Eur Urol Oncol. 2019 May 25. pii: S2588-9311(19)30061-6. doi: 10.1016/j.euo.2019.04.012. [Epub ahead of print]

PMID:
31133436
12.

Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.

Lotan Y, Inman BA, Davis LG, Kassouf W, Messing E, Daneshmand S, Canter D, Marble HT, Joseph AM, Jewell S, Boorjian SA.

J Urol. 2019 Nov;202(5):920-926. doi: 10.1097/JU.0000000000000355. Epub 2019 Oct 9.

PMID:
31120373
13.

Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.

Meleis L, Moore R, Inman BA, Harrison MR.

J Oncol Pharm Pract. 2020 Mar;26(2):330-337. doi: 10.1177/1078155219845434. Epub 2019 May 12.

PMID:
31081469
14.

A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.

Freedland SJ, Howard L, Allen J, Smith J, Stout J, Aronson W, Inman BA, Armstrong AJ, George D, Westman E, Lin PH.

Prostate Cancer Prostatic Dis. 2019 Sep;22(3):428-437. doi: 10.1038/s41391-019-0126-5. Epub 2019 Jan 21.

PMID:
30664736
15.

Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer.

Ingersoll MA, Li X, Inman BA, Greiner JW, Black PC, Adam RM.

Bladder Cancer. 2018 Oct 29;4(4):429-440. doi: 10.3233/BLC-180175.

16.

Molecular markers in bladder cancer.

Soria F, Krabbe LM, Todenhöfer T, Dobruch J, Mitra AP, Inman BA, Gust KM, Lotan Y, Shariat SF.

World J Urol. 2019 Jan;37(1):31-40. doi: 10.1007/s00345-018-2503-4. Epub 2018 Sep 26. Review.

17.

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. doi: 10.6004/jnccn.2018.0072.

PMID:
30181416
18.

Dietary patterns and health-related quality of life in bladder cancer survivors.

Gopalakrishna A, Chang A, Longo TA, Fantony JJ, Harrison MR, Wischmeyer PE, Inman BA.

Urol Oncol. 2018 Oct;36(10):469.e21-469.e29. doi: 10.1016/j.urolonc.2018.06.001. Epub 2018 Aug 17.

PMID:
30126776
19.

Heat-targeted drug delivery: A promising approach for organsparing treatment of bladder cancer.THERMODOX®.

Aminsharifi A, Brousell SC, Chang A, León J, Inman BA.

Arch Esp Urol. 2018 May;71(4):447-452. Review. Spanish, English.

PMID:
29745934
20.

Monopolar vs. bipolar transurethral resection for non-muscle invasive bladder carcinoma: A post-hoc analysis from a randomized controlled trial.

Liem EIML, McCormack M, Chan ESY, Matsui Y, Geavlete P, Choi YD, de Reijke TM, Farahat Y, Inman BA, de la Rosette JJMCH, Naito S.

Urol Oncol. 2018 Jul;36(7):338.e1-338.e11. doi: 10.1016/j.urolonc.2018.03.015. Epub 2018 Apr 13.

PMID:
29661592
21.

Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy.

Brousell SC, Fantony JJ, Van Noord MG, Harrison MR, Inman BA.

Core Evid. 2018 Jan 24;13:1-12. doi: 10.2147/CE.S118670. eCollection 2018. Review.

22.

What potential does plasmonics-amplified synergistic immuno photothermal nanotherapy have for treatment of cancer?

Vo-Dinh T, Inman BA.

Nanomedicine (Lond). 2018 Jan;13(2):139-144. doi: 10.2217/nnm-2017-0356. No abstract available.

23.

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2017 Oct;15(10):1240-1267. doi: 10.6004/jnccn.2017.0156.

PMID:
28982750
24.

Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study.

Shore ND, Boorjian SA, Canter DJ, Ogan K, Karsh LI, Downs TM, Gomella LG, Kamat AM, Lotan Y, Svatek RS, Bivalacqua TJ, Grubb RL 3rd, Krupski TL, Lerner SP, Woods ME, Inman BA, Milowsky MI, Boyd A, Treasure FP, Gregory G, Sawutz DG, Yla-Herttuala S, Parker NR, Dinney CPN.

J Clin Oncol. 2017 Oct 20;35(30):3410-3416. doi: 10.1200/JCO.2017.72.3064. Epub 2017 Aug 23. Erratum in: J Clin Oncol. 2019 Aug 20;37(24):2187.

25.

Synergistic Immuno Photothermal Nanotherapy (SYMPHONY) for the Treatment of Unresectable and Metastatic Cancers.

Liu Y, Maccarini P, Palmer GM, Etienne W, Zhao Y, Lee CT, Ma X, Inman BA, Vo-Dinh T.

Sci Rep. 2017 Aug 17;7(1):8606. doi: 10.1038/s41598-017-09116-1.

26.

Reporting Bias Leading to Discordant Venous Thromboembolism Rates in the United States Versus Non-US Countries Following Radical Cystectomy: A Systematic Review and Meta-analysis.

Fantony JJ, Gopalakrishna A, Noord MV, Inman BA.

Eur Urol Focus. 2016 Jun;2(2):189-196. doi: 10.1016/j.euf.2015.09.003. Epub 2015 Sep 26. Review.

PMID:
28723534
27.

Physical activity patterns and associations with health-related quality of life in bladder cancer survivors.

Gopalakrishna A, Longo TA, Fantony JJ, Harrison MR, Inman BA.

Urol Oncol. 2017 Sep;35(9):540.e1-540.e6. doi: 10.1016/j.urolonc.2017.04.016. Epub 2017 May 17.

28.

Reply to 'It May be Time to Abandon Urine Tests for Bladder Cancer'.

Furuya H, Rosser CJ, Inman BA, Fantony JJ.

J Natl Compr Canc Netw. 2017 May;15(5):lxx-lxxii. No abstract available.

PMID:
28476745
29.

Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.

Fantony JJ, Longo TA, Gopalakrishna A, Owusu R, Lance RS, Foo WC, Inman BA, Abern MR.

Cancer Biomark. 2017;18(4):381-387. doi: 10.3233/CBM-160261.

PMID:
28106542
30.

Anticipatory Positive Urine Tests for Bladder Cancer.

Gopalakrishna A, Fantony JJ, Longo TA, Owusu R, Foo WC, Dash R, Denton BT, Inman BA.

Ann Surg Oncol. 2017 Jun;24(6):1747-1753. doi: 10.1245/s10434-016-5763-5. Epub 2017 Jan 10.

PMID:
28074325
31.

Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.

Inman BA, Longo TA, Ramalingam S, Harrison MR.

Clin Cancer Res. 2017 Apr 15;23(8):1886-1890. doi: 10.1158/1078-0432.CCR-16-1417. Epub 2016 Nov 30. Review.

32.

NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.

Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C.

J Natl Compr Canc Netw. 2016 Oct;14(10):1213-1224.

33.

Targeted Exome Sequencing of the Cancer Genome in Patients with Very High-risk Bladder Cancer.

Longo T, McGinley KF, Freedman JA, Etienne W, Wu Y, Sibley A, Owzar K, Gresham J, Moy C, Szabo S, Greshock J, Zhou H, Bai Y, Inman BA.

Eur Urol. 2016 Nov;70(5):714-717. doi: 10.1016/j.eururo.2016.07.049. Epub 2016 Aug 9.

PMID:
27520487
34.
35.

The use of hyperthermia in the treatment of bladder cancer.

Crezee H, Inman BA.

Int J Hyperthermia. 2016 Jun;32(4):349-50. doi: 10.3109/02656736.2016.1163739. No abstract available.

PMID:
27353655
36.

The diagnostic accuracy of urine-based tests for bladder cancer varies greatly by patient.

Gopalakrishna A, Longo TA, Fantony JJ, Owusu R, Foo WC, Dash R, Inman BA.

BMC Urol. 2016 Jun 13;16(1):30. doi: 10.1186/s12894-016-0147-5.

37.

High rates of venous thromboembolic events in patients undergoing systemic therapy for urothelial carcinoma: A systematic review and meta-analysis.

Gopalakrishna A, Longo TA, Fantony JJ, Doshi U, Harrison MR, Van Noord M, Inman BA.

Urol Oncol. 2016 Sep;34(9):407-14. doi: 10.1016/j.urolonc.2016.05.009. Epub 2016 Jun 4. Review.

38.

A systematic review of regional hyperthermia therapy in bladder cancer.

Longo TA, Gopalakrishna A, Tsivian M, Van Noord M, Rasch CR, Inman BA, Geijsen ED.

Int J Hyperthermia. 2016 Jun;32(4):381-9. doi: 10.3109/02656736.2016.1157903. Epub 2016 May 1. Review.

39.

Lifestyle factors and health-related quality of life in bladder cancer survivors: a systematic review.

Gopalakrishna A, Longo TA, Fantony JJ, Van Noord M, Inman BA.

J Cancer Surviv. 2016 Oct;10(5):874-82. doi: 10.1007/s11764-016-0533-8. Epub 2016 Mar 21. Review.

40.

It May Be Time to Abandon Urine Tests for Bladder Cancer.

Fantony JJ, Inman BA.

J Natl Compr Canc Netw. 2015 Sep;13(9):1163-6. No abstract available.

PMID:
26358800
41.

Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?

Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, De Nunzio C, Okamura K, Kaasinen E, Solsona E, Ali-El-Dein B, Tatar CA, Inman BA, N'Dow J, Oddens JR, Babjuk M.

Eur Urol. 2016 Feb;69(2):231-44. doi: 10.1016/j.eururo.2015.05.050. Epub 2015 Jun 16. Review.

PMID:
26091833
42.

Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer.

Fantony JJ, Abern MR, Gopalakrishna A, Owusu R, Jack Tay K, Lance RS, Inman BA.

Urol Oncol. 2015 Sep;33(9):387.e1-6. doi: 10.1016/j.urolonc.2015.04.014. Epub 2015 May 28.

PMID:
26027762
43.

Effect of aerobic training on the host systemic milieu in patients with solid tumours: an exploratory correlative study.

Glass OK, Inman BA, Broadwater G, Courneya KS, Mackey JR, Goruk S, Nelson ER, Jasper J, Field CJ, Bain JR, Muehlbauer M, Stevens RD, Hirschey MD, Jones LW.

Br J Cancer. 2015 Mar 3;112(5):825-31. doi: 10.1038/bjc.2014.662. Epub 2015 Jan 13.

44.

Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with bladder cancer: does FISH positivity anticipate recurrence?

Seideman C, Canter D, Kim P, Cordon B, Weizer A, Oliva I, Rao J, Inman BA, Posch M, Herr H, Lotan Y.

World J Urol. 2015 Sep;33(9):1309-13. doi: 10.1007/s00345-014-1452-9. Epub 2014 Nov 25.

PMID:
25420920
45.

Thromboembolism and bleeding in bladder cancer.

Fantony JJ, Inman BA.

Oncology (Williston Park). 2014 Oct;28(10):847-54. Review.

46.

A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer.

Sousa A, Inman BA, Piñeiro I, Monserrat V, Pérez A, Aparici V, Gómez I, Neira P, Uribarri C.

Int J Hyperthermia. 2014 May;30(3):166-70. doi: 10.3109/02656736.2014.900194. Epub 2014 Apr 3.

PMID:
24697672
47.

Thermal dosimetry characteristics of deep regional heating of non-muscle invasive bladder cancer.

Juang T, Stauffer PR, Craciunescu OA, Maccarini PF, Yuan Y, Das SK, Dewhirst MW, Inman BA, Vujaskovic Z.

Int J Hyperthermia. 2014 May;30(3):176-83. doi: 10.3109/02656736.2014.898338. Epub 2014 Mar 26.

48.

Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency.

Hester W, Fry C, Gonzalez D, Cohen-Wolkowiez M, Inman BA, Ortel TL.

Thromb Res. 2014 Apr;133(4):629-33. doi: 10.1016/j.thromres.2013.11.019. Epub 2013 Nov 23.

49.

A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer.

Inman BA, Stauffer PR, Craciunescu OA, Maccarini PF, Dewhirst MW, Vujaskovic Z.

Int J Hyperthermia. 2014 May;30(3):171-5. doi: 10.3109/02656736.2014.882021. Epub 2014 Feb 3.

50.

Report of a rare fistula between a Studer neobladder and external iliac artery.

Kuntz NJ, Inman BA.

Can Urol Assoc J. 2013 Sep-Oct;7(9-10):E645-7. doi: 10.5489/cuaj.402.

Supplemental Content

Loading ...
Support Center